Feedback / Questions
Hernexeos (zongertinib) - Boehringer Ingelheim
Zongertinib in Pretreated HER2-Positive Salivary Gland Cancer
(ESMO Asia 2026)
-
Oct 1, 2026 -
Abstract #553O; Pres time: Dec 5, 2026; 05:07 PM - 05:17 PM; Location: Hall 401;
No abstract available
Oncology • Salivary Gland Cancer
•
HER-2
https://cslide.ctimeetingtech.com/asia2026/attendee/confcal/print/presentation/2957
Ye Guo
Oct 1, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next